SAT0604 Detection of TNF[alpha] Blockers and Anti-Drug's Antibodies Levels: A Comparison of Two Commercially Available Assays
Background Formation of antibodies (Ab) to TNFα blockers (adalimumab (ADA), etanercept (ETA) and infliximab (INF)) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti-drug antibody (anti-drug Ab) monitoring is hampered by lack of standardization....
Gespeichert in:
Veröffentlicht in: | Annals of the rheumatic diseases 2015-06, Vol.74, p.880 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background Formation of antibodies (Ab) to TNFα blockers (adalimumab (ADA), etanercept (ETA) and infliximab (INF)) inversely correlates with functional drug levels and clinical outcome. Comparison of drug levels and anti-drug antibody (anti-drug Ab) monitoring is hampered by lack of standardization. Objectives To determine the correlation and agreement between two different assays for measuring levels of TNFα blockers and anti-drug Ab. Methods Serum samples of 145 patients with autoimmune rheumatic diseases were evaluated in two different assays developed by Sanquin (Amsterdam, Netherlands (Assay A), and a commercially available kit from Progenica Biopharma (Derio, Spain) (Assay B) performed in the Centre of Laboratory Medicine at Vilnius University Hospital Santariskiu clinics. Results Assay A found detectable levels of ADA in 26 (96.3%), ETA - in 56 (88.9%), INF -in 35 (63.6%) patients, whereas Assay B these results were 26 (96.3%), 59 (93.7%) and 39 (70.9%), respectively. The good correlation was obtained when comparing Assay A vs. B in detecting drug levels (Spearman's rank correlation coefficient r=0.960, p |
---|---|
ISSN: | 0003-4967 1468-2060 |
DOI: | 10.1136/annrheumdis-2015-eular.2063 |